抗白點症病毒的胜肽疫苗之測試分析

蝦白點症病毒（White Spot Syndrome Virus, WSSV）是危害世界各地養殖蝦業的一株甲殼類病毒，白點症病毒具有感染力強、致死率高、宿主性廣等幾項特性，自1990年初期於亞洲第區爆發以來，每年均造成許多重大的損失，並迅速漫延到世界各地。白點症病毒為一新型態的病毒，其大部份蛋白質均與其他已知蛋白質無序列及親緣上的相關，因此在研究的困難度上較一般物種要來得更高。目前白點症病毒在感染的分子機制上仍尚未完全解開。 VP53A為白點症病毒封套上的蛋白質之一，完整基因全長有3,903 bp，可轉譯出1301個胺基酸，分子量估計為143.9 kDa。但經由質譜儀鑑定，發現在封套上主要以53 kDa的蛋白質C端形式存在，故命名為VP53A。本研究針對白點症病毒VP53A是否參與了病毒感染的過程進行了分析。以重組蛋白rVP53A進行活體感染阻斷試驗，並佐以Real-Time PCR與白點症病毒二階PCR檢測分析，發現先注射重組蛋白rVP53A的蝦子，在以注射白點症病毒感染後的存活率大幅提升，並且rVP53A阻斷病毒感染的能力與劑量相關。本研究初步建立了新的實驗模型：活體感染阻斷試驗。並推測白點症病毒封套蛋白VP53A可能在病毒感染的機制裡扮演了重要的角色，未來或許有機會發展成胜肽疫苗。

關鍵字

白點症病毒；活體感染阻斷

並列摘要

Since it first appeared in 1992, white spot syndrome virus (WSSV) has become the most threatening infectious agent in shrimp aquaculture. Within a decade, this pathogen has spread to all the main shrimp farming areas and has caused enormous economic losses. WSSV is a new virus in taxonomy, most of its proteins are not relative with all other known proteins in amino acid sequence (133 of 181), so it’s much more difficult to study this virus than others. Now the molecular mechanism of WSSV infection the host cell is unclear yet. VP53A is one of WSSV envelope proteins. There are 3903 bps in it’s DNA sequence that encoded into 1301 amino acids. But proteomic data indicates that VP53A (molecular weight 53 kDa) comprises the C terminus of WSSV067 that codes for a deduced protein of 150 kDa. We want to know if VP53A is involved in WSSV infection. We used a new experiment model, in vivo infection blocking assay, with a recombinant protein which is the partial region of VP53A, and checked the result by Real-Time PCR and WSSV 2-step PCR detection kit. We showed that the shrimps injected with rVP53A before infection of WSSV have a much higher survival rate. The data supports that rVP53A block WSSV infection in a dose-dependent manner. We preliminarily established a new experiment model, in vivo infection blocking assay and showed that VP53A might be a significant role in WSSV infection. Maybe VP53A has the potentiality to be a peptide antibody.

並列關鍵字

white spot syndrome virus ； WSSV ； VP53A ； in vivo infection blocking assay

參考文獻

Caipang, C. M., N. Verjan , Ooi, E. L., Kondo, H., Hirono, I., Aoki, T., Kiyono , H., Yuki, Y. (2008). "Enhanced survival of shrimp, Penaeus (Marsupenaeus) japonicus from white spot syndrome disease after oral administration of recombinant VP28 expressed in Brevibacillus brevis." Fish Shellfish Immunol.

Chen, L. L., Leu, J. H., Huang, C. J., Chou, C. M., Chen, S. M., Wang, C. H., Lo, C. F., Kou, G. H. (2002). "Identification of a nucleocapsid protein (VP35) gene of shrimp white spot syndrome virus and characterization of the motif important for targeting VP35 to the nuclei of transfected insect cells." Virology 293: 44-53.

Chen, L. L., Lu, L. C., Wu, W. J. Lo, C. F., Huang, W. P. (2007). "White spot syndrome virus envelope protein VP53A interacts with Penaeus monodon chitin-binding protein (PmCBP)." Dis Aquat Organ 74: 171-8.

Chou H.Y., Huang C.Y., Wang C.H., Chiang H.C. & Lo C.F. (1995). "Pathogenicity of a baculovirus infection causing white spot syndrome in cultured penaeid shrimp in Taiwan." Diseases of Aquatic Organisms 23: 165-173.

Fu, L. L., Li, W. F., Du, H. H., Dai, W., Xu, Z. R. (2008). "Oral vaccination with envelope protein VP28 against white spot syndrome virus in Procambarus clarkii using Bacillus subtilis as delivery vehicles." Lett Appl Microbiol 46: 581-6.

國際替代計量

抗白點症病毒的胜肽疫苗之測試分析

全文下載

主題瀏覽